Yes, Vraylar (cariprazine) is an atypical antipsychotic, also known as a second-generation antipsychotic. The FDA approved it in 2015, and it is currently used to treat three conditions: schizophrenia in adults, acute manic or mixed episodes in bipolar I disorder, and as an add-on to antidepressants for major depressive disorder.
What “Atypical Antipsychotic” Means
Antipsychotics fall into two generations. First-generation (or “typical”) antipsychotics, developed in the 1950s and 1960s, primarily block dopamine receptors in the brain. They work but carry a high risk of movement-related side effects like muscle stiffness and involuntary tremors. Second-generation (or “atypical”) antipsychotics, including Vraylar, were designed to treat the same symptoms with a different receptor profile, generally producing fewer of those movement side effects, though they can still occur.
Vraylar stands out among atypical antipsychotics because of how it interacts with dopamine receptors. Rather than simply blocking them, it acts as a partial agonist, meaning it can both stimulate and dampen dopamine activity depending on what’s needed. It has a particularly strong preference for a specific type of dopamine receptor called D3. In brain imaging studies, a low 1 mg daily dose occupied about 76% of D3 receptors but only 45% of D2 receptors. After about two weeks of regular dosing, Vraylar’s selectivity for D3 over D2 was roughly three to six times greater. This D3 preference is thought to contribute to its effects on motivation, cognition, and mood.
FDA-Approved Uses
Vraylar has three approved indications:
- Schizophrenia in adults: The recommended dose range is 1.5 mg to 6 mg once daily, starting at 1.5 mg.
- Manic or mixed episodes in bipolar I disorder: The dose range is 3 mg to 6 mg daily, starting at 1.5 mg and increasing to 3 mg on the second day.
- Major depressive disorder (added in 2022): Used as an add-on when an antidepressant alone hasn’t been enough. The dose starts at 1.5 mg and can increase to a maximum of 3 mg after two weeks. In clinical trials, patients qualified if they had less than 50% improvement on one to three prior antidepressants taken at adequate doses.
The maximum dose across all uses is 6 mg per day, which is notably lower than many other antipsychotics. Dose increases are recommended at intervals of no less than 14 days, because faster titration led to more side effects in clinical trials.
How Long It Stays in Your System
One unusual feature of Vraylar is its very long duration of action. The drug itself has an effective half-life of about 1.5 days, but it breaks down into active metabolites that continue working. The most important one, called DDCAR, has an effective half-life of about 7 days and a terminal half-life that can stretch to roughly 19 days. This means the medication’s effects, both therapeutic and side effects, can linger for weeks after you stop taking it. It also means the full impact of a dose change may not be apparent for several days.
Common Side Effects
The most frequently reported side effect is akathisia, a feeling of inner restlessness or an urge to keep moving. In a long-term study, about one in three patients (33%) experienced it. Other common side effects in that study included headache (17%), constipation (11%), and nausea (10%). Insomnia, sedation, vomiting, and restlessness each affected roughly 6% to 7% of patients.
Movement-related side effects beyond akathisia, collectively called extrapyramidal symptoms, were also notable. In studies of acute mania, these affected 10% to 25% of patients on Vraylar compared to 2% to 10% on placebo. These side effects tend to be dose-dependent: in bipolar depression trials, akathisia occurred in 5% to 6% of patients on the 1.5 mg dose but jumped to 6% to 14% on the 3 mg dose.
Weight Gain and Metabolic Effects
Weight gain is a well-known concern with atypical antipsychotics. Vraylar appears to have a relatively mild impact compared to others in its class. In clinical trials, patients gained between 0.5 kg and 1.1 kg (roughly 1 to 2.5 pounds). A real-world analysis estimated about 0.91 kg (2 pounds) of weight gain per year. For comparison, olanzapine and clozapine, two antipsychotics on the heavier end of the spectrum, are associated with average gains of 2.7 kg and 3.0 kg respectively. Data on blood sugar and cholesterol effects specifically with Vraylar remain limited.
Safety Warnings
Vraylar carries a boxed warning, the FDA’s most serious safety label, regarding elderly patients with dementia-related psychosis. Antipsychotic medications as a class raise the risk of death in this population, and Vraylar is not approved for that use. This warning applies to all antipsychotics, not just Vraylar specifically.